Journal of Neuro-Oncology

Journal

Publication Venue For

  • Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis.  141:289-301. 2019
  • Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study.  140:445-455. 2018
  • Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study.  140:341-349. 2018
  • UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts.  140:209-224. 2018
  • Multi-institutional study of treatment patterns in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study.  138:667-677. 2018
  • Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?.  138:163-171. 2018
  • Handedness and the risk of glioma.  137:639-644. 2018
  • SHP2 regulates proliferation and tumorigenicity of glioma stem cells.  135:487-496. 2017
  • Prediction of new brain metastases after radiosurgery: validation and analysis of performance of a multi-institutional nomogram.  135:403-411. 2017
  • Key rates for the grades and transformation ability of glioma: model simulations and clinical cases.  133:377-388. 2017
  • Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells.  132:219-229. 2017
  • Correlation of higher levels of soluble TNF-R1 with a shorter survival, independent of age, in recurrent glioblastoma.  131:449-458. 2017
  • A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.  129:487-494. 2016
  • A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.  129:139-146. 2016
  • What predicts early volumetric edema increase following stereotactic radiosurgery for brain metastases?.  127:303-311. 2016
  • Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.  125:123-131. 2015
  • miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients.  123:205-216. 2015
  • Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas.  122:585-593. 2015
  • Strong therapeutic potential of γ-secretase inhibitor MRK003 for CD44-high and CD133-low glioblastoma initiating cells.  121:239-250. 2015
  • Cognition in patients with newly diagnosed brain metastasis: Profiles and implications.  120:179-185. 2014
  • Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro.  118:61-72. 2014
  • Reproductive factors and risk of primary brain tumors in women.  118:297-304. 2014
  • Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.  120:361-370. 2014
  • Prediagnostic body weight and survival in high grade glioma.  114:79-84. 2013
  • Mutant tristetraprolin: A potent inhibitor of malignant glioma cell growth.  113:195-205. 2013
  • The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer.  112:467-472. 2013
  • Stereotactic radiosurgical treatment of brain metastasis of primary tumors that rarely metastasize to the central nervous system.  109:513-519. 2012
  • A functional polymorphism in the pre-miR-146a gene is associated with risk and prognosis in adult glioma.  105:639-646. 2011
  • Phase i and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas.  105:375-381. 2011
  • L1 stimulation of human glioma cell motility correlates with FAK activation.  105:27-44. 2011
  • Erratum: Cancer susceptibility variants and the risk of adult glioma in a US case-control study (Journal of Neuro-Oncology DOI: 10.1007/s11060-010-0506-0).  104:543. 2011
  • An NF-κB p65-cIAP2 link is necessary for mediating resistance to TNF-α induced cell death in gliomas.  102:367-381. 2011
  • Cancer susceptibility variants and the risk of adult glioma in a US case-control study.  104:535-542. 2011
  • Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: Results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.  101:57-66. 2011
  • Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme.  101:179-188. 2011
  • Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.  100:95-103. 2010
  • Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111.  95:199-209. 2009
  • Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness.  85:271-280. 2007
  • Pharmacologic manipulations of mitochondrial membrane potential (ΔΨm) selectively in glioma cells.  81:9-20. 2007
  • Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM).  80:261-274. 2006
  • 1p/19q chromosome deletions in metastatic oligodendroglioma.  80:203-207. 2006
  • Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines.  74:123-133. 2005
  • Radiation dosimetry of 131I-chlorotoxin for targeted radiotherapy in glioma-bearing mice.  71:113-119. 2005
  • Genetic and hypoxic regulation of angiogenesis in gliomas.  70:229-243. 2004
  • Caspase-1 mediates Fas-induced apoptosis and is up-regulated by interferon-γ in human astrocytoma cells.  67:167-176. 2004
  • Constitutive activation of the neuregulin-1/erbB signaling pathway promotes the proliferation of a human peripheral neuroepithelioma cell line.  66:273-284. 2004
  • Oncolytic viruses: Clinical applications as vectors for the treatment of malignant gliomas.  65:203-226. 2003
  • High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma.  65:127-134. 2003
  • Fas engagement increases expression of interleukin-6 in human glioma cells.  56:13-19. 2002
  • Expression of a restrictive receptor for interleukin 13 is associated with glial transformation.  48:103-111. 2000
  • Immunotherapy of a murine T cell lymphoma localized to the brain.  47:1-10. 2000
  • Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents..  46:135-144. 2000
  • Adenoid cystic carcinoma metastatic to the dura: Report of two cases.  44:267-273. 1999
  • Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion.  41:9-20. 1999
  • Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas.  36:191-198. 1998
  • Immunoreactivity of human MAb BT32/A6 with neuroepithelial tumors.  35:93-100. 1997
  • Fabrication and testing of a device capable of reducing the incidence of ventricular shunt promoted metastasis..  27:39-46. 1996
  • Expression of the CD44 adhesion molecule in tumours of the central and peripheral nervous system.  26:191-198. 1995
  • Multiple fraction-per-day radiotherapy for patients with brain stem tumors.  17:131-138. 1993
  • Partial characterization of glioma-derived growth factor 2: A novel mitogenic activity from human cell line D-54 MG.  17:99-109. 1993
  • Human glioblastoma cells produce 77 amino acid interleukin-8 (IL-877).  16:25-34. 1993
  • Medulloblastoma: tumor biological and clinical perspectives.  11:1-15. 1991
  • Growth factors derived from a human malignant glioma cell line, U-251MG.  7:225-235. 1989
  • The chemotherapy of posterior Fossa tumors in childhood.  5:217-229. 1987
  • Effect of methylprednisolone on radiotherapy of F344 rats with avian sarcoma virus induced gliomas.  4:309-313. 1987
  • Treatment of autochthonous rat brain tumors with steroid plus heparin: A brief report.  5:161-162. 1987
  • International Standard Serial Number (issn)

  • 0167-594X
  • Electronic International Standard Serial Number (eissn)

  • 1573-7373